BRPI0818672B8 - composições, composições farmacêuticas e usos de 2'flúor-2'-desoxitetra-hidrouridinas - Google Patents

composições, composições farmacêuticas e usos de 2'flúor-2'-desoxitetra-hidrouridinas

Info

Publication number
BRPI0818672B8
BRPI0818672B8 BRPI0818672A BRPI0818672A BRPI0818672B8 BR PI0818672 B8 BRPI0818672 B8 BR PI0818672B8 BR PI0818672 A BRPI0818672 A BR PI0818672A BR PI0818672 A BRPI0818672 A BR PI0818672A BR PI0818672 B8 BRPI0818672 B8 BR PI0818672B8
Authority
BR
Brazil
Prior art keywords
compositions
pharmaceutical compositions
deoxytetrahydrouridines
fluor
compounds
Prior art date
Application number
BRPI0818672A
Other languages
English (en)
Inventor
Duvall Bridget
V Ferraris Dana
S Hamilton Gregory
Lapidus Rena
Tsukamoto Takashi
Original Assignee
Eisai Inc
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40251685&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0818672(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai Inc, Otsuka Pharma Co Ltd filed Critical Eisai Inc
Publication of BRPI0818672A2 publication Critical patent/BRPI0818672A2/pt
Publication of BRPI0818672B1 publication Critical patent/BRPI0818672B1/pt
Publication of BRPI0818672B8 publication Critical patent/BRPI0818672B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

compostos 2'-flúor-2'-desoxitetra-hidrouridinas, uso dos mesmos e composições farmacêuticas. a presente invenção refere-se a alguns compostos de derivados de tetra-hidrouridina, a composições farmacêuticas e a kits que compreendem tais compostos e a métodos de fabricação e uso de tais compostos.
BRPI0818672A 2007-10-16 2008-10-16 composições, composições farmacêuticas e usos de 2'flúor-2'-desoxitetra-hidrouridinas BRPI0818672B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98039707P 2007-10-16 2007-10-16
US60/980,397 2007-10-16
PCT/US2008/080163 WO2009052287A1 (en) 2007-10-16 2008-10-16 2 ' -flu0r0-2 ' -deoxytetrahydrouridines as cytidine deaminase inhibitors

Publications (3)

Publication Number Publication Date
BRPI0818672A2 BRPI0818672A2 (pt) 2015-04-14
BRPI0818672B1 BRPI0818672B1 (pt) 2020-10-20
BRPI0818672B8 true BRPI0818672B8 (pt) 2021-05-25

Family

ID=40251685

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0818672A BRPI0818672B8 (pt) 2007-10-16 2008-10-16 composições, composições farmacêuticas e usos de 2'flúor-2'-desoxitetra-hidrouridinas

Country Status (40)

Country Link
US (4) US8268800B2 (pt)
EP (2) EP2447272B1 (pt)
JP (2) JP5496899B2 (pt)
KR (1) KR101543049B1 (pt)
CN (1) CN101827856B (pt)
AT (1) ATE548374T1 (pt)
BR (1) BRPI0818672B8 (pt)
CA (1) CA2702274C (pt)
CO (1) CO6270330A2 (pt)
CR (1) CR11427A (pt)
CY (3) CY1112781T1 (pt)
DK (1) DK2207786T3 (pt)
EA (1) EA018757B1 (pt)
EC (1) ECSP10010095A (pt)
ES (2) ES2616566T3 (pt)
FI (2) FIC20230040I1 (pt)
FR (2) FR23C1052I2 (pt)
GT (1) GT201000088A (pt)
HR (1) HRP20120419T1 (pt)
HU (2) HUS2300045I1 (pt)
IL (1) IL204732A (pt)
JO (1) JO2778B1 (pt)
LT (2) LTC2207786I2 (pt)
LU (2) LUC00326I9 (pt)
ME (1) ME00997B (pt)
MX (1) MX2010004109A (pt)
MY (1) MY147970A (pt)
NI (1) NI201000055A (pt)
NL (2) NL301256I2 (pt)
NO (2) NO2023047I1 (pt)
NZ (1) NZ584229A (pt)
PL (1) PL2207786T3 (pt)
PT (1) PT2207786E (pt)
RS (1) RS52323B (pt)
SA (1) SA08290661B1 (pt)
SI (1) SI2207786T1 (pt)
TW (1) TWI445539B (pt)
UA (1) UA99476C2 (pt)
WO (1) WO2009052287A1 (pt)
ZA (1) ZA201002178B (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US7964580B2 (en) * 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
JO2778B1 (en) * 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
HUE055911T2 (hu) 2008-05-15 2021-12-28 Celgene Corp Citidin-analógokat tartalmazó orális készítmények, és eljárások azok alkalmazására
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
US20100055047A1 (en) * 2008-08-26 2010-03-04 Yiyu Zou Methods for treating bronchial premalignancy and lung cancer
CL2009002206A1 (es) 2008-12-23 2011-08-26 Gilead Pharmasset Llc Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
ES2628609T3 (es) * 2009-04-06 2017-08-03 Otsuka Pharmaceutical Co., Ltd. Combinación de fármacos antineoplásicos a base de citidina con inhibidor de citidina deaminasa y uso del mismo en el tratamiento de cáncer
EP2417146B1 (en) * 2009-04-06 2016-07-13 Otsuka Pharmaceutical Co., Ltd. (2'-deoxy-ribofuranosyl)-1,3,4,7-tetrahydro-(1,3)diazepin-2-one derivatives for treating cancer
WO2010118010A1 (en) * 2009-04-06 2010-10-14 Eisai Inc. Combination of decitabine with cytidine deaminase inhibitor and use thereof in the treatment of cancer
US8609631B2 (en) 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
CL2011000716A1 (es) 2010-03-31 2012-04-20 Gilead Pharmasset Llc Formas cristalinas 1 6 de (s)-isopropil-2-(((s)-(((2r.3r.4r.5r)-5-(2,4-dioxo-3,4-dihidropirimidin-1(2h)-il)-4-fluoro-3-hidroxi-4-metil tetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato; composicion y combinacion farmaceutica; y su uso para tratar una infeccion por el virus de la hepatitis c.
WO2012075140A1 (en) 2010-11-30 2012-06-07 Pharmasset, Inc. Compounds
SI2709613T2 (sl) 2011-09-16 2020-12-31 Gilead Pharmasset LLC c/o Gilead Sciences, Inc. Postopki za zdravljenje HCV
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
NZ729172A (en) 2013-01-31 2018-06-29 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
JP2016529293A (ja) 2013-08-27 2016-09-23 ギリアド ファーマセット エルエルシー ２つの抗ウイルス化合物の組合せ製剤
RU2681939C2 (ru) 2013-10-29 2019-03-14 Оцука Фармасьютикал Ко., Лтд. Путь синтезирования 2'-дезокси-2'2'-дифтортетрагидроуридинов
JP6783224B2 (ja) 2014-04-04 2020-11-11 デル マー ファーマシューティカルズ 肺の非小細胞癌腫及び卵巣癌を処置するためのジアンヒドロガラクチトール及びその類縁体又は誘導体の使用
US10034872B2 (en) 2014-08-22 2018-07-31 Celgene Corporation Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
CA3007357C (en) 2015-12-03 2023-12-05 Epidestiny, Inc. Compositions containing decitabine, 5azacytidine and tetrahydrouridine and uses thereof
WO2017158396A1 (en) 2016-03-16 2017-09-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Cytidine deaminase inhibitors for the treatment of pancreatic cancer
AU2019216531A1 (en) 2018-02-02 2020-09-24 Maverix Oncology, Inc. Small molecule drug conjugates of gemcitabine monophosphate
WO2020047177A1 (en) * 2018-08-28 2020-03-05 Essenlix Corporation Assay accuracy improvement
US11224610B2 (en) * 2018-09-19 2022-01-18 Otsuka Pharmaceutical Co., Ltd. Low dose combination CDA substrate drug/cedazuridine with extended administration
CN112888700B (zh) * 2018-10-19 2025-03-04 因特欧力多公司 具有改善治疗功效的修饰核酸和含有其的抗癌药物组合物
WO2020080912A1 (ko) * 2018-10-19 2020-04-23 인터올리고 주식회사 치료 효능을 개선한 핵산 변형체 및 이를 포함하는 항암용 약학 조성물
US12187757B2 (en) * 2019-10-08 2025-01-07 Otsuka Pharmaceutical Co., Ltd. 2′-deoxy-2′,2′-difluorotetrahydrouridines with high purity and methods of making the same
EP4069254B1 (en) * 2020-02-25 2024-09-11 Otsuka Pharmaceutical Co., Ltd. Solid oral dosage forms comprising decitabine and cedazuridine
CN117835984A (zh) * 2021-03-26 2024-04-05 克利夫兰诊所基金会 使用胞苷脱氨酶抑制剂治疗rna病毒感染
WO2022254457A1 (en) * 2021-05-29 2022-12-08 Msn Laboratories Private Limited, R&D Center An improved process for the preparation of (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl) oxolan-2-yl]-4-hydroxy-1,3-diazinan-2one and its intermediate compounds
CN118354759A (zh) 2021-10-19 2024-07-16 阿基拉比奥有限公司 包含2’-脱氧胞苷类似物的组合物及其用于治疗镰状细胞病、地中海贫血和癌症的用途
WO2023076332A1 (en) * 2021-11-01 2023-05-04 St. John's University Injectable liquid pharmaceutical compostion containing gemcitabine and a cytidine deaminase inhibitor
US20230271996A1 (en) * 2021-12-25 2023-08-31 Scinopharm Taiwan, Ltd. Process for preparing cedazuridine
TW202410893A (zh) 2022-08-31 2024-03-16 日商大塚製藥股份有限公司 用於治療t細胞淋巴瘤之結合治療

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017606A (en) * 1973-10-04 1977-04-12 The Upjohn Company Organic compounds and process
US4210638A (en) * 1978-03-17 1980-07-01 Pcr, Inc. Antiviral composition and method of treating virus diseases
US4275057A (en) 1980-01-28 1981-06-23 The United States Of America As Represented By The Department Of Health, Education And Welfare Seven-membered ring compounds as inhibitors of cytidine deaminase
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
DE3481172D1 (de) 1983-10-26 1990-03-08 Sheldon B Greer Verfahren und materialien zum empfindlichmachen eines neoplastischen gewebes vor strahlung.
DE3587500T2 (de) 1984-12-04 1993-12-16 Lilly Co Eli Tumorbehandlung bei Säugetieren.
US4965374A (en) 1987-08-28 1990-10-23 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US5223608A (en) 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US5968914A (en) 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
WO1992018517A1 (en) 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
CA2086233C (en) 1991-04-23 1995-10-17 Wendy Oglevee-O'donovan In vitro leaf petiole multiplication of pelargoniums
FR2682112B1 (fr) 1991-10-08 1993-12-10 Commissariat A Energie Atomique Procede de synthese d'acide ribonucleique (arn) utilisant un nouveau reactif de deprotection.
US5594124A (en) 1992-06-22 1997-01-14 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2',2'-difluoropyrimidine nucleosides and 2'-deoxy-2'-fluoropyrimidine nucleosides and intermediates thereof
US5426183A (en) 1992-06-22 1995-06-20 Eli Lilly And Company Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5371210A (en) 1992-06-22 1994-12-06 Eli Lilly And Company Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5821357A (en) 1992-06-22 1998-10-13 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoropurine and triazole nucleosides
US5606048A (en) 1992-06-22 1997-02-25 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
WO1994019362A1 (en) 1993-02-23 1994-09-01 City Of Hope 4-ethoxy 5-fluoro 2'deoxyuridine
AU6081294A (en) 1993-05-14 1994-12-12 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
GB9311252D0 (en) 1993-06-01 1993-07-21 Hafslund Nycomed As Cell growth regualtors
US5637688A (en) 1994-12-13 1997-06-10 Eli Lilly And Company Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
US5521294A (en) 1995-01-18 1996-05-28 Eli Lilly And Company 2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides
WO1996026743A1 (en) * 1995-03-01 1996-09-06 Human Gene Therapy Research Institute Radiation enhanced gene therapy for treatment of tumors
US6001994A (en) 1995-12-13 1999-12-14 Eli Lilly And Company Process for making gemcitabine hydrochloride
US5760208A (en) 1996-08-14 1998-06-02 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Process to prepare pyrimidine nucleosides
AU3354500A (en) 1999-03-01 2000-09-21 Halogenetics, Inc. Dramatic simplification of a method to treat neoplastic disease by radiation
US6933287B1 (en) 1999-03-01 2005-08-23 Sheldon B. Greer Dramatic simplification of a method to treat neoplastic disease by radiation
EP1207783A1 (en) 1999-08-26 2002-05-29 Aortech International PLC Improvements relating to catheter positioning
US6462191B1 (en) 2000-07-13 2002-10-08 Air Products And Chemicals, Inc. Synthesis of 2-deoxy-2-fluoro-arabinose derivatives
CN100368422C (zh) 2000-11-29 2008-02-13 三井化学株式会社 L-核酸衍生物及其合成方法
EP1353693B1 (en) 2001-01-16 2005-03-16 Glaxo Group Limited Pharmaceutical combination containing a 4-quinazolineamine and paclitaxel, carboplatin or vinorelbine for the treatment of cancer
WO2002094844A2 (en) 2001-05-18 2002-11-28 Rakesh Kumar Antiviral nucleosides
JP2005508885A (ja) * 2001-07-31 2005-04-07 ザ ステイト オブ オレゴン， アクティング バイ アンド スルー ザ ステイト ボード オブ ハイヤー エデュケイション オン ビハーフ オブ ザ ユニバーシティー オブ オレゴン Ｄｎａメチル化の阻害剤
WO2003068162A2 (en) 2002-02-14 2003-08-21 Pharmasset Ltd. Modified fluorinated nucleoside analogues
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
AU2003278904A1 (en) 2002-09-24 2004-04-19 Kornis Pharmaceuticals, Incorporated 1, 3, 5-triazines for treatment of viral diseases
US7265096B2 (en) 2002-11-04 2007-09-04 Xenoport, Inc. Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
WO2005115410A2 (en) 2004-05-06 2005-12-08 University Of Rochester Context dependent inhibitors of cytidine deaminases and uses thereof
US20060014949A1 (en) 2004-07-13 2006-01-19 Supergen Inc. Compositions and formulations of decitabine polymorphs and methods of use thereof
WO2006015346A1 (en) 2004-07-30 2006-02-09 Pharmaessentia Corp. STEREOSELECTIVE SYNTHESIS OF β-NUCLEOSIDES
EP1819718A1 (en) 2004-12-08 2007-08-22 Sicor Inc. Difluoronucleosides and process for preparation thereof
WO2008085611A2 (en) * 2006-11-27 2008-07-17 University Of Miami Designer theraphy of pancreatic tumors
WO2009021551A1 (en) 2007-08-13 2009-02-19 Universite De La Mediterranee A method for assessing the risk of toxicity in a chemotherapy
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
WO2010047698A1 (en) 2008-10-22 2010-04-29 University Of Alabama At Birmingham Activation-induced cytidine deaminase inhibitor suppression of autoimmune diseases
ES2628609T3 (es) 2009-04-06 2017-08-03 Otsuka Pharmaceutical Co., Ltd. Combinación de fármacos antineoplásicos a base de citidina con inhibidor de citidina deaminasa y uso del mismo en el tratamiento de cáncer
US8609631B2 (en) 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer
EP2417146B1 (en) 2009-04-06 2016-07-13 Otsuka Pharmaceutical Co., Ltd. (2'-deoxy-ribofuranosyl)-1,3,4,7-tetrahydro-(1,3)diazepin-2-one derivatives for treating cancer
WO2010118010A1 (en) 2009-04-06 2010-10-14 Eisai Inc. Combination of decitabine with cytidine deaminase inhibitor and use thereof in the treatment of cancer

Also Published As

Publication number Publication date
ECSP10010095A (es) 2010-07-30
SA08290661B1 (ar) 2012-06-10
JP5859588B2 (ja) 2016-02-10
LTPA2023539I1 (pt) 2024-02-26
TWI445539B (zh) 2014-07-21
EP2447272A1 (en) 2012-05-02
FR23C1052I2 (fr) 2025-02-07
US20090137521A1 (en) 2009-05-28
HK1146410A1 (en) 2011-06-03
JP2011500713A (ja) 2011-01-06
NL301256I1 (pt) 2024-01-03
US20120289475A1 (en) 2012-11-15
BRPI0818672B1 (pt) 2020-10-20
HRP20120419T1 (hr) 2012-07-31
WO2009052287A1 (en) 2009-04-23
FR23C1051I1 (fr) 2024-01-26
JP5496899B2 (ja) 2014-05-21
IL204732A0 (en) 2010-11-30
AU2008312435A1 (en) 2009-04-23
JP2014177455A (ja) 2014-09-25
GT201000088A (es) 2012-03-13
KR20100091978A (ko) 2010-08-19
CA2702274A1 (en) 2009-04-23
EP2207786A1 (en) 2010-07-21
EA018757B1 (ru) 2013-10-30
CR11427A (es) 2010-08-16
TW200924786A (en) 2009-06-16
HUS2300044I1 (hu) 2024-01-28
CY2023029I1 (el) 2024-02-16
LUC00326I9 (pt) 2026-02-25
ME00997B (me) 2012-10-20
JO2778B1 (en) 2014-03-15
EP2447272B1 (en) 2017-02-01
NO2023047I1 (no) 2023-12-21
PT2207786E (pt) 2012-05-28
US20140186335A1 (en) 2014-07-03
NZ584229A (en) 2012-06-29
AU2008312435B2 (en) 2014-04-17
FR23C1051I2 (fr) 2025-02-07
US8951987B2 (en) 2015-02-10
CO6270330A2 (es) 2011-04-20
AU2008312435A8 (en) 2014-07-24
MX2010004109A (es) 2010-08-10
US9567363B2 (en) 2017-02-14
HUS2300045I1 (hu) 2024-01-28
LTC2207786I2 (pt) 2025-09-10
US20150210730A1 (en) 2015-07-30
ZA201002178B (en) 2011-05-25
LUC00326I2 (pt) 2026-02-02
FR23C1052I1 (fr) 2024-01-26
ES2384011T3 (es) 2012-06-28
ES2616566T3 (es) 2017-06-13
CY1112781T1 (el) 2016-02-10
FIC20230039I1 (fi) 2023-12-22
LUC00327I2 (pt) 2026-02-02
EP2207786B1 (en) 2012-03-07
BRPI0818672A2 (pt) 2015-04-14
US8618075B2 (en) 2013-12-31
PL2207786T3 (pl) 2012-09-28
CN101827856A (zh) 2010-09-08
NI201000055A (es) 2010-08-13
US8268800B2 (en) 2012-09-18
SI2207786T1 (sl) 2012-10-30
FIC20230040I1 (fi) 2023-12-22
CN101827856B (zh) 2013-02-06
EA201000642A1 (ru) 2010-10-29
DK2207786T3 (da) 2012-06-18
IL204732A (en) 2013-07-31
NL301256I2 (nl) 2024-01-11
NL301257I2 (nl) 2025-11-06
NO2023048I1 (en) 2023-12-21
KR101543049B1 (ko) 2015-08-07
CY2023028I1 (el) 2024-02-16
CA2702274C (en) 2015-12-29
RS52323B (sr) 2012-12-31
MY147970A (en) 2013-02-28
UA99476C2 (en) 2012-08-27
LTPA2023538I1 (pt) 2024-02-26
ATE548374T1 (de) 2012-03-15

Similar Documents

Publication Publication Date Title
ECSP10010095A (es) 2'-fluoro-2'-desoxitetrahidrouridinas como inhibidores de citidina desaminasa
CR10149A (es) Agentes citotóxicos que comprenden nuevos derivados de tomaimicina y su uso terapéutico
BRPI1015043A2 (pt) derivados de diazahomoadamantano e métodos de uso dos mesmos
BRPI0608604B8 (pt) moduladores de 2,3-dioxigenase de indolamina e composição farmacêutica
GT201000023A (es) Nuevos derivados de 6-trialzolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de met.
BRPI0815708A8 (pt) composto derivado de benzilbenzeno como inibidor de sglt, composição farmacêutica, e, uso de um composto
MX2008008152A (es) Compuestos heterociclicos biciclicos.
BRPI0819328A8 (pt) Compostos inibidores de replicação de vírus da imunodeficiência humana, composição farmacêutica e uso dos ditos compostos
ECSP109968A (es) Depsipéptidos cíclicos
BRPI0815170A2 (pt) Composição farmacêutica que compreende um inibidor de sglt 2
CR10381A (es) Uso de bifenilamidas de acido arilcarboxilico para el tratamiento de semillas
ECSP099619A (es) Anticuerpos anti-robo4 y sus usos
NI201000005A (es) Agentes citotóxicos que comprenden nuevos derivados de tomaimicina y su uso terapéutico.
HN2008001393A (es) Derivados de 1,2,4,5- tetrahidro -3h- benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
BRPI0815079A2 (pt) Composto dericado de 1,2-diamido-etileno, composição farmacêutica que contém e uso desse composto
CL2008003712A1 (es) Compuestos derivados de tiadiazololoxifenilamidina o tiazoliloxifenilamidina; su procedimiento de preparacion; uso y procedimiento para combatir microorganismos no deseados; agente que comprende a dichos compuestos; compuestos intermediarios; y su procedimiento de preparacion.
UY29767A1 (es) Derivados de benzotiazolonas, procesos para su preparación, composiciones farmacéuticas que los contienen y aplicaciones
BRPI0605926A2 (pt) ciclopentanos substituìdos ou ciclopentanonas como agentes terapêuticos
ECSP109874A (es) Nuevos compuestos 892
BRPI0620985B1 (pt) composição farmacêutica, e usos de derivados de triazina e sensibilizadores de insulina
ECSP045271A (es) Derivados de quinolina
CY1110787T1 (el) Νεα μορφινικα παραγωγα
PA8668901A1 (es) Derivados de tetrahidronaftalina, procedimientos para su preparacion y su uso como antiinflamatorios

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: OTSUKA PHARMACEUTICAL CO., LTD (JP)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 20/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/10/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF